An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04076059 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone Sensitive Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Placebo
DRUG: Androgen deprivation therapy (ADT)

Sponsor

Astellas Pharma China, Inc.